EUVIMEDObjevte EUVIMED
Übersichtsarbeit

CRISPR‐interceded CHO cell line development approaches

Shahin Amiri iD, Setare Adibzadeh iD, Samaneh Ghanbari iD, Behnaz Rahmani iD, Mohammad H Kheirandish iD, Aref Farokhi-Fard iD, Mansoureh S Dastjerdeh iD, Fatemeh Davami iD

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28329 ↗

At a glance

Übersichtsarbeit in Biotechnology and Bioengineering, 2023. Written by Shahin Amiri and 7 co-authors. Institution: Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Major MEDLINE topics: Gene Editing, CRISPR-Cas Systems. Cited 22 times so far (Crossref); 171 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

For industrial production of recombinant protein biopharmaceuticals, Chinese hamster ovary (CHO) cells represent the most widely adopted host cell system, owing to their capacity to produce high‐quality biologics with human‐like posttranslational modifications. As opposed to random integration, targeted genome editing in genomic safe harbor sites has offered CHO cell line engineering a new perspective, ensuring production consistency in long‐term culture and high biotherapeutic expression levels. Corresponding the remarkable advancements in knowledge of CRISPR‐Cas systems, the use of CRISPR‐Cas technology along with the donor design strategies has been pushed into increasing novel scenarios in cell line engineering, allowing scientists to modify mammalian genomes such as CHO cell line quickly, readily, and efficiently. Depending on the strategies and production requirements, the gene of interest can also be incorporated at single or multiple loci. This review will give a gist of all the most fundamental recent advancements in CHO cell line development, such as different cell line engineering approaches along with donor design strategies for targeted integration of the desired construct into genomic hot spots, which could ultimately lead to the fast‐track product development process with consistent, improved product yield and quality.

Subjects

MeSH terms (MEDLINE)

Gene EditingCRISPR-Cas SystemsCricetinaeAnimalsHumansCricetulusCHO CellsRecombinant Proteins

Author keywords

CRISPR-Cas9Chinese hamster ovarycell line developmentdonor designtargeted integration

Substances

Recombinant Proteins

Authors and institutions

  • Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Department of Medical Biotechnology, School of Advanced Technologies, Tehran University of Medical Sciences, Tehran, Iran.

ORCID profiles: Shahin Amiri, Setare Adibzadeh, Samaneh Ghanbari, Behnaz Rahmani, Mohammad H Kheirandish, Aref Farokhi-Fard, Mansoureh S Dastjerdeh, Fatemeh Davami

Cite

APA

Amiri, S., Adibzadeh, S., Ghanbari, S., Rahmani, B., Kheirandish, M. H., Farokhi-Fard, A., Dastjerdeh, M. S., & Davami, F. (2023). CRISPR‐interceded CHO cell line development approaches. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28329

Vancouver

Amiri S, Adibzadeh S, Ghanbari S, Rahmani B, Kheirandish MH, Farokhi-Fard A, et al. CRISPR‐interceded CHO cell line development approaches. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28329

BibTeX
@article{Amiri2023,
  author = {Amiri, Shahin and Adibzadeh, Setare and Ghanbari, Samaneh and Rahmani, Behnaz and Kheirandish, Mohammad H and Farokhi-Fard, Aref and Dastjerdeh, Mansoureh S and Davami, Fatemeh},
  title = {CRISPR‐interceded CHO cell line development approaches},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28329}
}
Start for free →